Safety, Tolerability, and Pharmacokinetics of High‐Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers
- 4 August 2021
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 110 (5) , 1337-1348
Abstract
Compared with intravenous formulations, subcutaneous (s.c.) formulations of therapeutic monoclonal antibodies may provide increased patient access and more convenient administration options, although historically high‐volume s.c. administration (> 10–15 mL) has been challenging. We report results from two phase I studies in healthy participants (GP29523 and GP40201) that evaluated s.c. crenezumab, an anti‐Aβ monoclonal antibody in development for individuals at risk for autosomal‐dominant Alzheimer’s disease. GP29523 assessed safety, tolerability, and pharmacokinetics (PK) in 68 participants (aged 50–80 years) who received single ascending doses (600–7,200 mg) of crenezumab or placebo (4–40 mL). GP40201 assessed safety, tolerability, and PK in 72 participants (aged 18–80 years) who received different combinations of dose (1,700–6,800 mg), infusion volume (10–40 mL), and flow rate (2–4 mL/minute), with/without recombinant human hyaluronidase (rHuPH20). There were no serious or dose‐limiting adverse events in either study. There were no meaningful differences in pain scores among reference placebo (4 mL), test placebo (4–40 mL), or crenezumab (600–7,200 mg) in GP29523, or across treatments with varying infusion volume, flow rate, dose, or rHuPH20 co‐administration or concentration in GP40201. Transient erythema was the most common infusion site reaction in both studies. In GP40201 at volumes of ≥ 20 mL, rHuPH20 co‐administration appeared to reduce infusion site swelling incidence, but, in some cases, was associated with larger areas of infusion site erythema. Crenezumab exhibited approximately dose‐proportional PK, and s.c. bioavailability was 66% and independent of dose or rHuPH20 co‐administration. High‐dose, high‐concentration, high‐volume s.c. crenezumab formulated with/without rHuPH20 was well‐tolerated in healthy participants, with an acceptable safety profile.Keywords
Funding Information
- Roche
This publication has 21 references indexed in Scilit:
- Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy SubjectsAAPS PharmSciTech, 2015
- Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast CancerThe Journal of Clinical Pharmacology, 2013
- Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiencyJournal of Allergy and Clinical Immunology, 2012
- An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of AJournal of Neuroscience, 2012
- Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approachAdvances in Therapy, 2011
- Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteersCurrent Medical Research and Opinion, 2009
- Subcutaneous immunoglobulin: opportunities and outlookClinical and Experimental Immunology, 2009
- Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st centuryAnnals of Allergy, Asthma & Immunology, 2008
- Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administrationExpert Opinion on Drug Delivery, 2007
- Structural and functional changes of normal aging skinJournal of the American Academy of Dermatology, 1986